Bristol Myers (BMY) Gets a Buy Rating from BMO Capital


BMO Capital analyst Alex Arfaei maintained a Buy rating on Bristol Myers (BMY) today and set a price target of $60. The company’s shares opened today at $51.06.

According to TipRanks.com, Arfaei is a 5-star analyst with an average return of 8.5% and a 70.2% success rate. Arfaei covers the Healthcare sector, focusing on stocks such as Elanco Animal Health Inc, Merck & Company, and Eli Lilly & Co.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bristol Myers with a $56.50 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $70.05 and a one-year low of $44.30. Currently, Bristol Myers has an average volume of 14.27M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It includes chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.